Article ; Online: Intravenous Hemin, a potential heme oxygenase-1 activator, does not protect from post-ERCP acute pancreatitis in humans: Results of a randomized multicentric multinational placebo-controlled trial.
Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.
2024 Volume 24, Issue 3, Page(s) 363–369
Abstract: Objective: Hemin, a heme oxygenase 1 activator has shown efficacy in the prevention and treatment of acute pancreatitis in mouse models. We conducted a randomized controlled trial (RCT) to assess the protective effect of Hemin administration to prevent ... ...
| Abstract | Objective: Hemin, a heme oxygenase 1 activator has shown efficacy in the prevention and treatment of acute pancreatitis in mouse models. We conducted a randomized controlled trial (RCT) to assess the protective effect of Hemin administration to prevent post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) in patients at risk. Methods: In this multicenter, multinational, placebo-controlled, double-blind RCT, we assigned patients at risk for PEP to receive a single intravenous dose of Hemin (4 mg/kg) or placebo immediately after ERCP. Patients were considered to be at risk on the basis of validated patient- and/or procedure-related risk factors. Neither rectal NSAIDs nor pancreatic stent insertion were allowed in randomized patients. The primary outcome was the incidence of PEP. Secondary outcomes included lipase elevation, mortality, safety, and length of stay. Results: A total of 282 of the 294 randomized patients had complete follow-up. Groups were similar in terms of clinical, laboratory, and technical risk factors for PEP. PEP occurred in 16 of 142 patients (11.3%) in the Hemin group and in 20 of 140 patients (14.3%) in the placebo group (p = 0.48). Incidence of severe PEP reached 0.7% and 4.3% in the Hemin and placebo groups, respectively (p = 0.07). Significant lipase elevation after ERCP did not differ between groups. Length of hospital stay, mortality and severe adverse events rates were similar between groups. Conclusion: We failed to detect large improvements in PEP rate among participants at risk for PEP who received IV hemin immediately after the procedure compared to placebo. Trial registration number: ClinicalTrials.gov number, NCT01855841). |
|---|---|
| MeSH term(s) | Animals ; Mice ; Humans ; Heme Oxygenase-1 ; Hemin ; Cholangiopancreatography, Endoscopic Retrograde/adverse effects ; Administration, Rectal ; Anti-Inflammatory Agents, Non-Steroidal/therapeutic use ; Pancreatitis/etiology ; Lipase |
| Chemical Substances | Heme Oxygenase-1 (EC 1.14.14.18) ; Hemin (743LRP9S7N) ; Anti-Inflammatory Agents, Non-Steroidal ; Lipase (EC 3.1.1.3) |
| Language | English |
| Publishing date | 2024-02-15 |
| Publishing country | Switzerland |
| Document type | Randomized Controlled Trial ; Multicenter Study ; Journal Article |
| ZDB-ID | 2056680-3 |
| ISSN | 1424-3911 ; 1424-3903 |
| ISSN (online) | 1424-3911 |
| ISSN | 1424-3903 |
| DOI | 10.1016/j.pan.2024.02.009 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 5553: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.